Table 1 Clinical characteristics of the study population (n = 26).

From: Severe COVID-19 associated hyperglycemia is caused by beta cell dysfunction: a prospective cohort study

 

T0 aseline

T3 Visit after 3 months

T6 Visit after 6 months

p

n

26

26

26

Age [years]

59.0 ± 9.9

59.0 ± 9.9

59.0 ± 9.9

Sex [n female, %]

9 (35%)

9 (35%)

9 (35%)

Prevalence hyperglycemia [n, %]

17 (65%)

n.a.

13 (50%)

0.04

BMI [kg/m²]

30.4±4.8

31.6±4.7

31.6±4.6

<0.0001

Body weight [kg]

91.0±15.4

94.3±15.9

94.7±15.3

<0.0001

WHR

0.94 ± 0.08

0.94 ± 0.08

0.93 ± 0.08

0.11

Fat mass [%]

24 ± 10

24 ± 10

26 ± 13

0.30

Systolic blood pressure [mmHg]

132 ± 16

133 ± 16

135 ± 18

0.37

Diastolic blood pressure [mmHg]

84 ± 7

85 ± 8

84 ± 9

0.98

First random glucose [mmol/L]

6.5 (6.0, 7.5)

Fasting glucose [mmol/L]

5.4 ± 1.1

5.7 ± 0.5

5.4 ± 0.6

0.83

Glucose after 2 h [mmol/L]

9.1±2.5

n.a.

7.6±1.8

<0.001

Fasting insulin [mIU/L]

13.0 (9.1, 17.5)

14.2 (10.9, 16.7)

7.7 (6.2, 13.4)

0.01

Insulin after 2 h [mIU/L]

77.8 (49.5, 109.2)

n.a.

48.2 (36.7, 121.9)

0.06

Fasting C-peptide [pmol/L]

890±272

706±265

558±215

<0.0001

C-peptide after 2 h [pmol/L]

3340±792

n.a.

2312±716

<0.0001

Fasting NEFA [mmol/L]

0.96±0.25

n.a.

0.77±0.27

0.001

NEFA after 2 h [mmol/L]

0.57±0.20

n.a.

0.34±0.14

<0.0001

Fasting glycerol [µmol/L]

260±72

n.a.

156±47

<0.0001

Glycerol after 2 h [µmol/L]

218±53

n.a.

121±25

<0.0001

Insulinogenic index

1.17 (0.85, 1.70)

n.a.

1.49 (0.81, 1.53)

0.29

Insulin sensitivity index

3.23±1.41

n.a.

4.53±2.30

0.003

Disposition index

4.83 ± 4.20

n.a.

4.89 ± 2.58

0.86

HOMA-beta

1.59 (1.14, 2.50)

n.a.

1.01 (0.81, 1.53)

0.01

HOMA-IR

2.62 (1.97, 4.93)

n.a.

1.77 (1.48, 3.42)

0.01

HbA1c [mmol/mol]

47.4±13.4

35.6 ± 4.3

37.8±4.2

<0.001

Triglycerides [mmol/L]

1.76 ± 0.89

1.72 ± 1.28

1.50 ± 0.83

0.08

Total cholesterol [mmol/L]

4.36 ± 0.84

5.19 ± 1.14

4.77 ± 0.92

0.11

HDL cholesterol [mmol/L]

1.30 ± 0.34

1.20 ± 0.26

1.19 ± 0.33

0.16

LDL cholesterol [mmol/L]

2.26±0.77

3.31±1.06

2.91±0.90

0.01

ALT [μkat/L]

1.11±0.58

0.49±0.18

0.46±0.19

<0.0001

AST [μkat/L]

0.49±0.20

0.38±0.09

0.36 ± 0.11

0.001

Urea [mmol/L]

5.59 ± 2.80

5.40 ± 1.47

5.76 ± 1.42

0.73

Creatinine [μmol/L]

68.7±15.4

74.4±15.1

75.8±15.6

<0.001

Albumine [g/L]

40.3±1.9

47.1±6.1

43.0±2.6

<0.0001

Cortisol [nmol/L]

258 ± 184

n.a.

249 ± 99

0.81

TSH [µmol/L]

1.89 (1.50, 2.66)

n.a.

1.51 (1.23, 1.85)

<0.001

Triiodothyronine (T3) [pmol/L]

5.25±0.72

n.a.

5.74±0.52

0.01

Thyroxine (T4) [pmol/L]

15.9±3.7

n.a.

14.5±1.9

0.03

White blood cells [×109/L]

9.65±4.11

6.68±1.65

6.08±1.67

<0.001

Platelets [×109/L]

234 ± 112

247 ± 61

211 ± 57

0.26

D-dimer [μg/L]

925 (340, 2140)

590 (310, 860)

250 (210, 530)

<0.001

Baecke Score

6.54±1.31

7.61±1.56

7.58±1.49

0.005

  1. Normally distributed variables were expressed as mean ± standard deviation and skewed distributed variables as median and interquartile range.
  2. P-values for differences between T0 and T6 were calculated with paired T-test for normal distributed variables, with Wilcoxon signed-rank test for skewed distributed variables and via Chi-square test for categorical variables.
  3. Statistically significant values are shown in bold.